A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: UCB Biopharma S.P.R.L.
Prior Safety Data
Approved in 2 jurisdictions
Trial Summary
What is the purpose of this trial?Hidradenitis suppurativa (HS) is a painful, long-term skin condition that causes abscesses and scarring on the skin.
Eligibility Criteria
Treatment Details
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: BimekizumabExperimental Treatment1 Intervention
Subjects will receive one Bimekizumab loading dose 1 and several Bimekizumab dose 2 applications.
Group II: AdalimumabActive Control1 Intervention
Subjects will receive one Adalimumab loading (dose 1) and several Adalimumab dose 2 and dose 3 applications.
Group III: PlaceboPlacebo Group1 Intervention
Subjects will receive several placebo applications to keep the blinding.
Bimekizumab is already approved in European Union, United States for the following indications:
🇪🇺 Approved in European Union as Bimzelx for:
- Moderate to severe plaque psoriasis
- Active psoriatic arthritis
- Non-radiographic axial spondyloarthritis
- Active ankylosing spondylitis
🇺🇸 Approved in United States as Bimzelx for:
- Moderate-to-severe plaque psoriasis
- Active psoriatic arthritis
- Non-radiographic axial spondyloarthritis
- Active ankylosing spondylitis
- Hidradenitis suppurativa
Find a clinic near you
Research locations nearbySelect from list below to view details:
Hs0001 119Coral Gables, FL
Hs0001 117Tampa, FL
Hs0001 123Hershey, PA
Hs0001 115Las Vegas, NV
More Trial Locations
Loading ...
Who is running the clinical trial?
UCB Biopharma S.P.R.L.Lead Sponsor
UCB Biopharma SRLLead Sponsor